USE OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS

被引：0

作者：

Chermensky, A. G. ^{[1
]}

Gembitskaya, M. E. ^{[1
]}

机构：

[1] St Petersburg State Med Univ, Pulmonol Res Inst, St Petersburg, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2010年 / 82卷 / 08期

关键词：

mucoviscidosis; cystic fibrosis; inhaled tobramycin; PSEUDOMONAS-AERUGINOSA;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The results of a few studies evaluating the efficacy and safety of nebulized tobramycin solution used in patients with cystic fibrosis have been published to date. Pulmonary deposition of inhaled tobramycin and its lung produced concentrations are rather high (10-25 times greater than the minimum suppressing concentration) and systemic absorption is extremely low. The treatment makes it possible to improve external respiratory function, to lower the colonization of the bronchi with Pseudomonas aeruginosa, and, in many cases, to achieve its eradication. Inhaled tobramycin reduces the sputum level of inflammatory cytokines in patients with cystic fibrosis, which slows down irreversible lung changes. Inhaled antibacterial therapy results in a reduction in the number of exacerbations, the frequency of admissions, and the need for systemic antibiotics.

引用

页码：76 / 78

页数：3

共 12 条

[1]

AVDEYEV SN, 2009, LECHEB DELO, V2, P80

[2] Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis [J].

Barker, AF ;

Couch, L ;

Fiel, SB ;

Gotfried, MH ;

Ilowite, J ;

Meyer, KC ;

O'Donnell, A ;

Sahn, SA ;

Smith, LJ ;

Stewart, JO ;

Abuan, T ;

Tully, H ;

Van Dalfsen, J ;

Wells, CD ;

Quan, J .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (02) :481-485

[3]

CHERMENSKY AG, 2009, 9 NATS KONGR MUKOVIS, P85

[4]

CHERMENSKY AG, 2009, 11 NATS KONGRESSA MU, P86

[5]

DODGE JA, 2006, EUR RES J, V20, P4

[6] Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis [J].

Geller, DE ;

Pitlick, WH ;

Nardella, PA ;

Tracewell, WG ;

Ramsey, BW .

CHEST, 2002, 122 (01) :219-226

[7]

GEMBITSKAYA TYE, 2008, VRACH, V3, P38

[8] Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa [J].

Grotta, Milena Baptistella ;

de Sa Camargo Etchebere, Elba Cristina ;

Ribeiro, Antonio Fernando ;

Romanato, Juliana ;

Goncalves de Oliveira Ribeiro, Maria Angela ;

Ribeiro, Jose Dirceu .

JORNAL BRASILEIRO DE PNEUMOLOGIA, 2009, 35 (01) :35-43

[9] Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis [J].

Husson, MO ;

Wizla-Derambure, N ;

Turck, D ;

Gosset, P ;

Wallaert, B .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :247-249

[10]

Kapranov N., 2008, PULMONOLOGY, V3, P20

← 1 2 →